Talecris Biotherapeutics makes Hypermune products without latex
Hypermune products now latex-free
10/5/07Talecris Biotherapeutics has eliminated latex from its line of Hypermune (hyperimmune globulin therapies) products. The move allows doctors to use Talecris merchandise, such as vials and syringes, on patients with latex allergies. "Product safety remains a top priority at all levels of our research and manufacturing organizations," said Steve Petteway, Ph.D., senior VP of research and development at Talecris. In addition, the company received approval from the FDA to include hyperimmune labeling information on the removal of pathogenic prions during manufacturing. "These two advances provide an improved overall margin of safety for our Hypermunes," Petteway said.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.
